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7Dr  Marie-Paule Kieny is a Director of research at the institut national 
de la Santé et de la recherche Médicale (inSerM) in Paris, where 
she assists the French President of the Organization on international 
institutional Collaboration  
Along her professional life, Dr. Marie-Paule Kieny has influenced the 
strategic development of several organisations through participation 
in their Executive Board and she also chaired the Scientific Advisory 
Board of many international organisations Thus, she is:
-  Chair of the executive Board of the Drugs for neglected 
Diseases initiative (DnDi), Geneva, Switzerland
-  Chair of the Governance Board of the Medicines Patent Pool 
Foundation (MPPF), Geneva, Switzerland
-  Secretary of the Board of the Global Antibiotics research and 
Development Partnership (GArDP), Geneva, Switzerland
-  Member of the Board of the Human Vaccine Project (HVP, new 
york, USA)
-  independent Director, bioMérieux, lyon, France
-  Chair of the Wellcome Trust Joint Strategic Advisory Group, 
london, UK
Her work is focused on universal health coverage and sustainable de-
velopment, with one of the main aspects being the development of 
strategies to deliver vaccines and essential medicines to the communi-
8ties at the lowest possible price, especially in low- and middle-income 
countries 
That’s the reason why Dr  Marie-Paule Kieny is awarded with a Honoris 
Causa by the Universitat Autònoma de Barcelona, in recognition of 
the values of solidarity that she expresses and  transmits through her 
focus on diseases that specially affect developing countries 
Dr  Kieny received her PhD in Microbiology from the University of 
Montpelier in 1980, where she was also awarded a University Diploma 
in economics  She received her Diplôme d’Habilitation à Diriger des 
recherches from the University of Strasbourg in 1995  
Dr  Marie-Paule Kieny has published over 350 articles and reviews 
and directed the research of many doctoral candidates and undergrad-
uates, mainly in the areas of infectious diseases, immunology, vaccin-
ology, and health systems 
Before joining World Health Organization (WHO) in 2001, Dr  Kieny 
held top research positions in the public and private sectors in France, 
which included Director of r&D Programmes of Transgene S A , from 
1981 to 1988, and Director of research and Head of the Hepatitis C 
Virus Molecular Virology Group at the institute of Virology of the 
inSerM, from 1999 to 2000 
Dr  Kieny’s research career at Transgene S A , from Project leader up 
to Director of r&D Programmes, led to the development of a novel re-
combinant rabies vaccine, which drove elimination of rabies in europe 
and north America  She also worked on the design of several original 
AiDS vaccine candidates in collaboration with the Pasteur institute, and 
conducted research on immuno-gene therapy targeting breast and cervi-
cal cancers, with encouraging results  During this time, she published 
almost 200 publications in a high impact journals, between them 4 pub-
lications in nature and 1 in Science, and was awarded 10 patents 
9During this years Dr  Marie-Paule Kieny also was: 
-  Member of the Virology/Immunology Scientific Committee 
of the Association pour la recherche contre le Cancer (ArC), 
Paris, France
-  Chair of WHO/TDr steering committee on Vaccine Discovery 
research (VDr), Geneva, Switzerland
-  Member of the Virology Scientific Committee of the Agence 
nationale pour la recherche sur le SiDA (AnrS), Paris, France
-  Chair of the Biomed external expert Monitoring panel of the 
european Framework Program 4, Brussels, Belgium
-  Chair of the Quality of life external expert Monitoring panel of 
the european Framework Program 5 (FP5), Brussels, Belgium
-  Member of WHO/TDr steering committee on Malaria vaccines 
(iMMAl), Geneva, Switzerland
In 2001 she moved to the WHO, initially as a Scientific Officer and 
from 2002 to 2010 as Director of the WHO initiative for Vaccine 
research  Major successes under her leadership were the development 
and licensing of new vaccines against meningitis A and against pan-
demic influenza in developing countries through transfer of technol-
ogy and know-how  The development and implementation of health 
technologies against poverty-related diseases and those that dispro-
portionately affect poor and marginalized populations are continuing 
priorities since her first role in WHO with the Special Programme for 
research and Training in Tropical Diseases in 2001 
During the 2009 influenza pandemic she led the WHO Pandemic 
Influenza Deployment Initiative which was instrumental in delivering 
more than 80 million doses of vaccine to nearly 80 low- and middle-
income countries  
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During this time Dr  Marie-Paule Kieny also was: 
-  Member of the Science Advisory Board in Health of the 
european Commission Framework Program 7 (FP7), Brussels, 
Belgium
-  Chair of the Scientific Advisory Board (SAB) of the Jenner 
institute, Oxford, UK
-  Member of the Board of Trustees (BOT) of the international 
Vaccine institute (iVi), Seoul, republic of Korea
-  Member of the Scientific Advisory Group (SAG) of the 
international Vaccine institute (iVi), Seoul, republic of Korea
-  Member of the Scientific Consultants Group (SCG) of the 
Malaria Vaccine Development Program of the U S  Agency for 
international Development (USAiD), Washington DC, USA
-  Member of the Scientific Advisory Committee (SAC) of the 
european Vaccine initiative (eVi), Heidelberg, Germany 
– previously european Malaria Vaccine initiative (eMVi), 
Copenhagen, Denmark
-  Member of the european Developing Country Clinical 
Trials Partnership (eDCTP) Partnership Board, The Hague, 
netherlands
-  Member of the Scientific Advisory Committee of the 
international AiDS Vaccine initiative (iAVi), new york, USA
-  Member of the Board of Counsellors (BOC) of the Pediatric 
Dengue Vaccine initiative (PDVi) at iVi, Seoul, republic of Korea
-  Member of the Project Management Subcommittee (Chair 
from 2003 to 2010) of the international AiDS Vaccine initiative 
(iAVi), new york, USA
-  Advisor to the Director-General of inSerM, Paris, France in 
the fields of Biotechnology and Innovation 
From 2010 to 2017, Dr  Marie-Paule Kieny served as the Assistant 
Director-General for Health Systems and innovation at the World 
Health Organization  Her main mandate was to support develop-
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ing countries strengthening their health systems towards Universal 
Health Coverage  She was also in charge between August 2014 and 
September 2016 of ebola r&D for WHO, and she oversaw the design 
and implementation in Guinea of the only clinical trial which success-
ful demonstrated the efficacy of an Ebola vaccine. 
From May 2015 to June 2017, she led the implementation of the WHO 
r&D Blueprint, a global preparedness plan for action against emerg-
ing diseases’ epidemics with the aim to accelerate the availability of 
medical technologies during epidemics by focusing on a list of priori-
tized emerging diseases for which medical countermeasures are insuf-
ficient or nonexistent. 
in WHO, she oversaw more than 250 staff, assisted by a group of 9 
directors, with a budget of over US$ 115 million per year  
During this time she also was:
-  Member of the Advisory Group for Societal Challenge 
“Health, demographic change and wellbeing” of the european 
Commission Horizon 2020, Brussels, Belgium 
-  Member of the Hilleman labs Strategic Advisory Group (SAG), 
Delhi, india
-  Member of the executive Board of the Health Metrics network, 
Geneva, Switzerland
-  Member of the executive Board of the Global Health Workforce 
Alliance, Geneva, Switzerland
Dr  Marie-Paule Kieny has also received several prizes and distinctions:
-  Prix de l’innovation rhône-Poulenc 
-  Prix Génération 2000-impact Médecin 
-  Chevalier de l’Ordre national du Mérite, au titre du Ministère 
de la recherche
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-  Chevalier de la légion d’Honneur, au titre du Ministère des 
Affaires etrangères
-  Prix international de l’inserm
Finally, i would like to repeat and emphasize that beyond her ex-
traordinary Curriculum Vitae, what has been really impressive in Dr  
Marie-Paule Kieny professional achievements is her constant and ex-
cellent work on low- and middle-income countries in order to:
-  Get universal health coverage and sustainable development 
where every child, man and woman can afford and has access to 
the quality essential medicines, vaccines and diagnostics they 
need to lead a healthy and productive life 
-  Make vaccines and essential medicines available to the whole 
population at the lowest possible price 
-  Transfer technology and know-how for the development and 
implementation of health technologies against poverty-related 
diseases and those that disproportionately affect poor and mar-
ginalized populations 
-  Decrease the impact of public health emergencies through ac-
celerating the availability of medical technologies during epi-
demics; promoting international sharing of data and results 
during public health emergencies and developing a regulatory 
policy for research and development of vaccines for public 
health emergencies 
it is for all these reasons that it is my pleasure, my honour and my 
privilege to request that the rector of the Universitat Autònoma de 








Madame la rectrice, Monsieur le Secrétaire Général, professors of 
the Universitat Autònoma de Barcelona, thank you very much  i am 
humbled and very proud at the same time to have been awarded this 
title of Doctor honoris causa of your great university 1
So, it is a pleasure to address this audience  i will describe to you my 
journey, which brought me from research to vaccine development and 
to global health, ending up at where i am now - and i am very glad that 
you recognise me for this - an activist for health for all  
My lecture is thus on Vaccines to Global Health  As a rebellious ado-
lescent in the early 1970s i swore that would never, ever study medi-
cine nor work in health  My two parents were medical doctors and my 
two younger brothers ended up being also medical doctors, so i’m the 
black swan in this family  i thought i needed to do something different 
and i wanted to do teach agriculture in Africa, helping the population 
getting out of poverty  
Accordingly, i didn’t study medicine, i competed and was selected to 
join the national School of Agronomy in Montpellier and i ended up 
as an engineer in agronomy  i wanted to work in what is now called 
This is an adapted transcription of the lecture by Marie-Paule Kieny on the occasion of her being 
awarded the Honorary Doctorate from the Universitat Autònoma de Barcelona  At some points during 
her address Dr  Kieny makes reference to the slides in her presentation 
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the irD, the ‘institute for international Development’ (institut de 
recherche pour le Développement)  But when i was twenty, the irD 
director presented the institute to my schoolmates and i and bluntly 
said, “i’m so happy to see so many girls in this room”, we were sort 
of shocked but pleasantly surprised  And then he added, “because it 
will be less competition for you – the boys”! 1973  less competition 
because how would you young girls think you can do anything doing 
agriculture in Africa???
The world has changed, as you know  So, i didn’t study medicine, and 
I didn’t do agriculture after all. I finally did a PhD, and started to work 
in one of the first French biotechs, Transgene, located in Strasbourg. 
My very first project in 1981 was to develop a vaccine against rabies  
At the time when we started this project in 1981, what was the situ-
ation with human rabies? There was a very rough estimate of 60,00 
cases in total, mainly in Asia  The African number is certainly under-
estimated because nobody really knew what was happening in Africa, 
but very few cases in europe and the Americas 
rabies is an infectious disease transmitted to humans by animals  
While domestic animals like cows, cats and dogs can transmit the dis-
ease, it is mainly transmitted by wild animals  in continental europe, 
across russia and in north America foxes were the main vectors and 
they were responsible for transmitting rabies to domestic animals, 
who then infected humans  The years 1980 were the early days of 
molecular biology. The first step was to identify the antigen and to 
isolate and sequence the viral genome- and this had been done by the 
Wistar institute scientists in Philadelphia  From there you could either 
go down the chemical route and synthesise peptides to use as candi-
date vaccines, or you could express the coding sequence in a new host 
For rabies this was tried with absolutely no success  it took us a few 
months to finally produce a recombinant live vaccine based on the 
vaccinia virus, which produces the glycoprotein of the rabies virus  
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We obtained a glycoprotein whose phenotypic profile was very simi-
lar to that of rabies virus antibodies, and this seemed to be a good 
candidate for a vaccine  So where did we go from there? remember, 
this was the early 1980s  
First we immunised mice  We saw that our candidate vaccine was very 
efficacious because if you look at ‘protection’ here (the diamonds) you 
can see that you can protect 100% of mice with only 0 01ml of in vitro 
cell culture supernatant  The next step was to published our results 
in Nature  These results generated a little controversy, as highlighted 
by the title of an article published in newswatch: ‘Cowpox-cloned 
rabies vaccine, highly effective – cheap but controversial’  indeed, 
the recombinant vaccine was based on vaccinia virus, which has been 
used since edward Jenner as smallpox vaccine  Since the 1970s and 
the eradication of smallpox, vaccinia virus was not used in man any-
more and health officials were not willing to consider using vaccinia 
in humans again because it had a track record of severe side-effects  
As further development as a human vaccine was blocked, we were 
very lucky to work with scientists in Belgium who were trying to find 
a solution to eliminate and eradicate rabies in foxes  They showed that 
foxes could be vaccinated through the oral route, just by administra-
tion of 0 01 ml of cell culture supernatant  And so what??? Do you try 
and catch all the foxes around and administer vaccine with a pipette? 
That doesn’t really work 
We collaborated with the Mérial company, which developed a bait to 
encapsulate vaccine filled in a small plastic bag  The baits had a smell 
which attracted foxes and were resistant to climatic factors – tempera-
ture, UV light, etc  They could be dropped by helicopter in forests and 
places where foxes come to feed  
The first vaccination campaign was carried out in a small area of 
10,000 km2 between France and Belgium. Following five vaccination 
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campaigns rabies cases nearly disappeared in both wild and domestic 
animals  Based on this success, the vaccine was used to eliminate ra-
bies from europe  
So how long did it take to get from the start of the project to the 
large-scale implementation of vaccination campaigns? The cloning of 
a gene was done in the early 1980s  in 1984 we constructed the re-
combinant vaccine  We started immunisation of foxes in captivity in 
1986. The first field trial took place in 1987 and trials ended in 1991  
Marketing started in 1993, so it took ten years to get from the concept 
to use in the field. 
So, thanks to this project i had got closer to health    but i had not done 
anything in Africa yet…
leaving Transgene, i started in WHO in 2000, where i was responsible 
for vaccine research and development. One of my first projects there 
was to develop a vaccine against meningitis  A change in the busi-
ness model for medical innovation was imperative  indeed, in spite 
of epidemic meningitis A striking sub-Saharan Africa every year, no 
vaccine manufacturer was interested in producing a vaccine against 
meningitis A because there was no market in the rich world  After the 
1996 epidemic which peaked at nearly 200,000 cases of meningitis A, 
the international committee said, ‘this cannot continue’  
A group of international experts and African ministries endorsed the 
project to develop a conjugate meningitis A vaccine for Africa  The 
Bill and Melinda Gates Foundation provided $70m to a ten-year part-
nership – starting in 2001 - between WHO and PATH, an international 
nGO, to eliminate epidemic meningitis as a public health problem in 
sub-Saharan Africa through the development, testing, licensure and 
use of conjugate meningococcal vaccines  Consultations with African 
officials brought to the conclusion that the vaccine needed to cost less 
than 50 cents a dose if we wanted to have it sustainably introduced 
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into Africa  The project set up a partnership with Serum institute of 
india ltd, a very large vaccine manufacturer in india  The company 
agreed to work with the WHO and PATH to manufacture vaccine at 
a target price of less than 50 cents a dose  The conjugation method 
was developed by FDA in the USA and was transferred and scaled 
up at Serum institute of india  The objective was to start with mass 
vaccination to interrupt transmission of the bacteria in the population  
After a few years of development and clinical testing, the first vaccine 
introduction took place in 2010 in 1- to 29-year olds in three countries 
of the meningitis belt: Burkina Faso, Mali and Niger, with financial 
support for the Gavi Alliance 
Between 2010 and 2017, at least 300,000 cases and 30,000 deaths 
were averted in the African meningitis belt through mass vaccination 
of 300 million people with the conjugate meningitis A vaccine  The 
project was led entirely by the public sector along with an nGO in 
collaboration with a ‘generic’ manufacturer in india 
in 2014 i was asked by Dr  Margaret Chan, the then Director-General 
of WHO, to lead on behalf of the Organization on the clinical devel-
opment of a vaccine against ebola in the context of a Public Health 
emergency of international Concern  in spite of ebola having been 
there for quite a number of years, no vaccine was available because 
there was no profit to be made. In spite of that, a number of vac-
cines had been researched but none had reached clinical evaluation  
Two vaccines were the most advanced  The GSK product was based 
on a non-replicating chimpanzee adenovirus (ChAd-eBO), and the 
newlink product, which had been developed by PHAC, the Canadian 
health authority, was based on a live VSV virus (VSV-eBO)  newlink 
vaccine was later bought by Merck  For these two candidate vaccines, 
Phase 1 clinical trial started in September and October 2014, respec-
tively  WHO took the responsibility to organised clinical trials of the 
VSV-based vaccine in Hamburg, in Geneva, in Kilifi (Kenya) and in 
lambarene (Gabon) 
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Thanks to so much goodwill from so many people, there were enough 
safety and immunogenicity data to decide that it was possible to move 
forward with Phase 3 efficacy trials in West Africa with both vaccine can-
didates  in March 2015, in the midst of the epidemic, a consortium made 
of the Guinean Ministry of Health, MSF, the norwegian Government and 
WHO started the Phase 3 clinical trial of an ebola vaccine in Guinea  The 
trial was called ‘Ebola ça suffit’ and used the VSV-EBO vaccine 
At that time there two other consortia were starting Phase 3 evalua-
tion of the candidate vaccines in liberia and in Sierra leone, using 
a randomized, placebo-control and a cluster-randomized trial design, 
respectively  Following extensive consutation among the WHO con-
sortium, there was a decision to use another strategy that would add 
value to these other two Phase 3 trials  
The design chosen for the “Ebola ça suffit” trial was based on a strat-
egy which had been used to eradicate smallpox, and which was called 
ring vaccination  How did this work? As soon as there was a new case 
of smallpox, in spite of vaccinating the whole district or province, 
vaccinators identified the contacts of the smallpox case and the con-
tact of these contacts  These persons formed the group which was then 
vaccinated to prevent further transmission  So, great for eradication 
but how can you use this strategy for a vaccine clinical trial? 
The ring vaccination trial starts with the identification of a newly lab-
oratory-confirmed case of Ebola. Around this case vaccinators define 
the socio-geographical ring of contacts and contacts of contacts  And 
then as soon the ring determined, it received a randomization number 
which dictated whether it would be either vaccinated immediately or 
after 21 days  The rings vaccinated after 21 days served as controls 
for the ones vaccinated immediately  Thus, the ring vaccination trial 
belongs to the larger group of cluster-randomised trials and efficacy 
was determined by comparison of the number of ebola cases in rings 
vaccinated immediately, compared with those vaccinated at 21 days  
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intermediate results became available in July 2015 and were published in 
August, 5 months after the start of the trial  The table shows that, in the 
clusters vaccinated immediately, all the ebola cases occurred before ten 
days after vaccination  in the clusters vaccinated at day 21, there were 
of course more cases because day 0 was the day when vaccination oc-
curred in the clusters vaccinated immediately  nevertheless, no case was 
reported in the delayed clusters after 10 days after vaccination  Therefore 
these intermediate results – zero versus sixteen cases in the immediate 
versus delayed vaccination rings, respectively – showed that the VSV-
EBO vaccine was likely to be very efficacious. This vaccine, although not 
registered yet, is currently used in north Kivu in the Democratic republic 
of Congo, where more than 50,000 people have already been vaccinated  
What did we learn during ebola? We learned that it is possible to ac-
celerate r&D during emergencies and that it is feasible to safely and 
effectively implement research interventions in an affected country, 
even though there had not been any clinical research before 2014 in 
any of the three countries  it also highlighted the fact that it is im-
perative to advance r&D preparedness before an epidemic  To this ef-
fect, WHO initiated in 2015 the ‘r&D Blueprint for Action to Prevent 
epidemics – accelerating r&D and saving lives’  There are three lines 
of work: improving coordination and fostering an enabling environ-
ment for research; accelerating research and development processes; 
and developing norms and standards adapted to the epidemic context  
i left the WHO in June 2017and since this time i have been a director 
of research at insem, where one of my focusses is on access to and 
pricing of medicine  This topic is important for low and middle in-
comes, but it also becomes more and more important for high-income 
countries  indeed, public finances cannot sustain the current skyrock-
eting increase in the pricing of medicines  
Let us first look at the situation with HiV, tuberculosis and hepatitis C  
Although there was a lot of progress in the last two decades for HiV, with 
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nearly 21 million people now on treatment, more than 16 million per-
sons (more than 40%) remain untreated despite the fact that treatments 
available  The case of tuberculosis is even more dramatic – only 2 per 
cent of people who need treatment for drug resistant TB have access to 
it, because the manufacturer is not willing to provide licenses to generic 
manufacturers or to lower prices  likewise, only three million patients 
(4 per cent of the 71 million people who live with hepatitis C) have ac-
cess to treatment, whereas there is medicine available which is 100 per 
cent curative  Why is that? Price and absence of generics is one reason  
The Sofosbuvir-Daclatasvir regimen is priced (for a 12-week course) at 
142,000 US$ in the USA while in France it stands at US$ 50,000  This 
contrasts sharply with the production cost, which is estimated at US$ 50  
But the high price of medicines is not only a problem with new innova-
tive drugs  indeed, when a generic manufacturer purchased the rights for 
epiPen, a treatment against septic shock which has been long off patent, 
it increased over a 10 years time the price from 100 to nearly 700 dollars  
in preparation for moderating a session for students, i recently looked 
at what the internet says about return on investment for the pharma-
ceutical sector, I was very surprised to find that the first ten hits talk 
about the current financial model not being sustainable because of the 
high cost of research  This seem to contradict data published in the 
Financial Times showing that Health Technologies is bay far the most 
profitable industry in 2015, at 21% average profit margin. 
Finally, i would like to discuss briefly two Foundations of which I have 
the honour to chair the governance Board since 2017, DnDi and MPP  
DnDi, the Drugs for neglected Diseases initiative, was created 15 years 
ago following receipt in 1999 by MSF of the nobel Prize  MSF made 
a commitment to invest the value of the prize in the creation of DnDi 
in order to develop drugs for the most neglected tropical diseases and 
allow the people who needed these drugs to have access to them  
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After 15 years of existence, DnDi has a mature and dynamic portfolio 
with 39 r&D projects, has incubated GArDP, an initiative to develop 
new antibiotics, is developing new chemical entities and has raised 
more than US$ 500 million  DnDi has already delivered seven treat-
ments for malaria, leishmaniasis, Chagas disease, paediatric HiV and 
sleeping sickness  Following close collaboration with DNDi, Sanofi 
obtain in 2018 an article 58 european Medicines Agency authorisa-
tion for Fexinidazole, an oral drug for sleeping sickness, one of the 
most horrible neglected tropical diseases  We are also on track to de-
liver 16-18 new treatments by 2023 
MPP, the Medicines Patent Pool, aims to decrease the price of innova-
tive medicines through generic manufacturing  MPP negotiates vol-
untary licences with patent holders and sub-licences them to generic 
manufacturers in low- or middle-income countries  Though generic 
competition, major price decreases ensure access of the best drugs to 
the people who need them in poor countries  MPP has currently li-
cences for 13 antiretroviral drugs, three drugs against hepatitis C, and 
one tuberculosis treatment  This has led to 130 ongoing pharmaceuti-
cal development projects with generic manufacturers, to the delivery 
of six billion doses of treatment, especially for HiV, and to half a bil-
lion dollars saving for the global health community through access to 
cheaper drugs 
MPP is now trying to see how the Patent Pool model can be adapted 
to other medicines, and especially medicines against diabetes, cardio-
vascular diseases or cancer 
So, in conclusion    i haven’t done any agriculture! Africa has been the 
focus for much of my work but for sure, i have been working all my 
professional life in health 





reCTOrA De lA UAB
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Avui la nostra universitat ha nomenat doctora honoris causa la Sra  
Marie-Paule Kieny en el marc de la celebració del cinquantè aniversa-
ri de la fundació de la UAB, en l’eix de la solidaritat 
Congratulations, Dra  Kieny 
És un honor i un plaer tenir-la a partir d’ara com a membre del Claustre 
de professors de la UAB 
la Dra  Kieny, com molt bé ens ha descrit el seu padrí, el Dr  Pumarola, 
ha demostrat en la seva trajectòria personal i professional un compro-
mís indiscutible amb l’ajuda a les persones desfavorides  Ha lluitat 
per aconseguir una àmplia disponibilitat de medicaments, en parti-
cular vacunes, per a les persones de països tercers on, a causa de les 
dificultats econòmiques, educatives i socials, és molt difícil garantir 
als ciutadans la medicació adequada per a la seva salut  Per tant, crec 
que queden clars el seu perfil personal i professional en l’àmbit de la 
solidaritat, i les raons que han portat el Consell de Govern de la UAB 
a proposar-la com doctora honoris causa 
Aquesta universitat té clar, i així ho expressen els nostres estatuts, que 
les nostres activitats s’inspiren en els principis de llibertat, democrà-
cia, justícia, igualtat i solidaritat 
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En aquest sentit, s’han definit en el nostre ordenament jurídic les fun-
cions de la Universitat al servei de la societat  i, de manera general, 
s’ha d’entendre que la Universitat té com un dels seus objectius prio-
ritaris el de ser factor de desenvolupament, orientació crítica i trans-
formació de la societat en la qual s’insereix  És a dir, crec que ha de 
subratllar-se que la Universitat exerceix una funció social, s’incardina 
plenament en la societat, serveix els interessos de la societat i hi influ-
eix, i, amb el coneixement generat i transmès, pretén també transfor-
mar-la  Aquesta és també la responsabilitat social de la Universitat, és 
a dir, el seu compromís amb la societat 
en aquest àmbit de la relació Universitat/societat, la UAB sempre ha 
donat la màxima rellevància a la solidaritat i, per aquesta raó, ha tre-
ballat en dos grans àmbits: la cooperació al desenvolupament i l’acció 
social  Moltes persones (professors, PAS i estudiants de la nostra co-
munitat universitària) de forma voluntària treballen en diversos pro-
jectes, iniciatives i accions de solidaritat 
Així mateix, la recerca en l’àmbit de les vacunes i d’una salut global 
ha estat una de les línies a les quals la Dra  Kieny ha dedicat grans 
esforços, com avui hem pogut constatar quan el Dr  Pumarola ha fet la 
defensa del doctorat honoris causa  i és, amb aquesta recerca, que ha 
impulsat polítiques per afavorir l’accés als medicaments a ciutadans 
de països amb grans dificultats socials i econòmiques 
Sense cap dubte, a la UAB la recerca es considera un dels objectius 
essencials de la nostra raó de ser com a universitat, recerca entesa 
com a fonament i garantia d’una docència de qualitat, com a mitjà 
per al progrés de la societat i de la mateixa comunitat universitària 
i com a ampliació i transferència de coneixements en tots els àmbits 
del saber, element cabdal de la seva relació amb la societat  Per tant, 
també des d’aquesta recerca cal treballar per incrementar polítiques 
solidàries que permetin el desenvolupament social de les dones i els 
homes d’aquest món global, com ho ha fet la Dra  Kieny 
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l’actuació de la UAB es basa en uns valors cívics que inspiren el com-
promís, la responsabilitat, la igualtat de totes les persones i els seus 
drets i l’acció de rebuig davant les situacions d’injustícia i desigualtat 
social  
Per això no tenim cap dubte que la Dra  Kieny ha lluitat, i continua 
lluitant, per la igualtat i els drets de totes les persones, sense que el 
seu origen, raça, sexe, religió, país d’origen, etcètera s’interposin per-
què els drets de les persones es preservin de forma integral  i és així 
com, a partir de la seva formació com a microbiòloga i immunòloga, 
ha dedicat una gran part de la seva vida a aconseguir medicaments i 
vacunes que garanteixin la salut de les persones en aquests països poc 
desenvolupats, on, a causa de la manca de condicions de vida salubres 
(educació, alimentació, sanitat, ambient, etcètera), la vida hi és difícil 
i l’esperança de vida, curta 
Gràcies, Dra  Kieny, per la vostra contribució a fer un món millor, més 
just, més igualitari, més segur i segurament més feliç 
el seu exemple ens ha de servir per avançar en el compromís amb la 
lluita contra les injustícies socials treballant en particular per:
1  Facilitar una vida digna als ciutadans dels pobles on els con-
flictes socials, la fam, les persecucions i la salut els obliguen 
a emigrar 
2  Garantir als homes i dones amb discapacitats unes condicions 
adequades per facilitar-los un desenvolupament integral en el 
nostre campus i en la nostra societat 
3  Fer possible que, a la UAB, totes les persones lGTB puguin 
gaudir del dia a dia sense cap discriminació 
4  Garantir que totes les dones tinguin les mateixes possibilitats 
de desenvolupament personal i professional en el nostre cam-
pus i que no hagin de patir cap discriminació o assetjament 
per raons de gènere 
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Col·laborar amb aquells països on la transferència del nostre conei-
xement pugui ser d’utilitat per millorar la seva formació/educació, 
desenvolupament i apoderament 
estic segura que la Dra  Kieny ha tingut sempre clares totes aquestes 
coses i que ha fet tot el que estava en les seves mans per millorar-les, 
sigui des del laboratori, des de les fundacions i institucions on ha tre-
ballat, des del treball de camp allà on els problemes l’han portada i, en 
particular, des de la seva contribució a l’OMS  
Gràcies, Dra  Kieny, per haver acceptat de formar part del nostre 
claustre  És un honor tenir-la, a partir d’ara, entre nosaltres  
estic segura que d’ara endavant comptarem amb la seva «saviesa» 
per millorar i que ella podrà comptar amb nosaltres per desenvolupar 
projectes solidaris 
Moltes felicitats de nou, Dra  Marie-Paule Kieny 
Congratulations, again 






Dr  Marie-Paule Kieny is currently Director of research at inserm (institut 
national de la santé et de la recherche médicale) in Paris, where she assists 
the President on international institutional Collaboration  
Dr  Kieny serves as the Chair of the Board of the Drugs for neglected 
Diseases initiative (DnDi, Geneva, Switzerland) and of the Medicines Pa-
tent Pool Foundation (MPPF, Geneva, Switzerland) since July and August 
2017, respectively  She is also a member of the Board of the Global An-
tibiotic research and Development Partnership (GArDP, Geneva, Swit-
zerland) and of the Human Vaccine Project (HVP, new york, USA) and a 
non-executive independent Director of bioMérieux (lyon, France)  
Between October 2010 and June 2017, she served as Assistant Director-Gene-
ral at the World Health Organization and was in charge of Health Systems and 
innovation  She strived in particular towards the vision of a world where every 
child, man and woman can afford and has access to the quality essential medi-
cines, vaccines and diagnostics they need to lead a healthy and productive life 
in WHO, she oversaw more than 250 staff, assisted by a group of 9 direc-
tors, with a budget of over US$ 115 million per year  
in addition to her main work on Health Systems, Marie-Paule Kieny was 
in charge between August 2014 and September 2016 of ebola r&D for 
WHO, and she oversaw the design and implementation in Guinea of the 
only clinical trial which successful demonstrated the efficacy of an Ebola 
vaccine  Since May 2015, she leads the implementation of the WHO r&D 
Blueprint for action against epidemics 
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Prior to this, Dr  Kieny directed the WHO initiative for Vaccine research 
since its inception in 2001  Major successes under her leadership were the 
development and licensing of a new vaccines against meningitis A and 
against pandemic influenza in developing countries through transfer of te-
chnology and know-how  The development and implementation of health 
technologies against poverty-related diseases and those that disproportio-
nately affect poor and marginalized populations are continuing priorities 
since her first role in WHO with the Special Programme for Research and 
Training in Tropical Diseases in 2001  
In 2009-2010 she led the WHO Pandemic Influenza Deployment Initiative 
which was instrumental in delivering more than 80 million doses of vacci-
ne to nearly 80 low- and middle-income countries  
Before coming to WHO, Dr  Kieny held top research positions in the pu-
blic and private sectors of her home country, France  The positions inclu-
ded Assistant Scientific Director of Transgene S.A. from 1981 to 1888, 
and Director of research and Head of the Hepatitis C Virus Molecular 
Virology Group at the institute of Virology, institut national de la santé et 
de la recherche médicale (inSerM) during 1999-2000 
Dr  Kieny’s research career at Transgene S A  led to the development of a 
novel recombinant rabies vaccine, which drove elimination of rabies in eu-
rope and north America  She also worked on the design of several original 
AiDS vaccine candidates in collaboration with the Pasteur institute, and 
conducted research on immuno-gene therapy targeting breast and cervical 
cancers, with encouraging results  
Marie-Paule Kieny influenced the strategic development of several organi-
sations through participation in their executive Board  She also chaired the 
Scientific Advisory Board of many international organisations.
Dr  Kieny directed the research of many doctoral candidates and under-
graduates  She has published over 250 articles and reviews, mainly in the 
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Since 9-2017:  Chair of the Governance Board of the Medicines Patent 
Pool Foundation (MPPF), Geneva, Switzerland
Since 8-2017:  independent Director, bioMérieux, lyon, France
Since 7-2017:  Chair of the executive Board of the Drugs for neglected 
Diseases initiative (DnDi), Geneva, Switzerland
Since 7-2017:  Chair of the Wellcome Trust Joint Strategic Advisory Group, 
london, UK
2015-2017:   Member of the european Commission Horizon 2020 Ad-
visory Group for Societal Challenge “Health, demographic 
change and wellbeing”, Brussels, Belgium
2009-2017:  Member of the Hilleman labs Strategic Advisory Group 
(SAG), Delhi, india
2010-2013:  Member of the executive Board of the Health Metrics ne-
twork, Geneva, Switzerland
2012-2016:   Member of the executive Board of the Global Health Work-
force Alliance, Geneva, Switzerland
2006-2012:  Member of the european Commission Framework Program 7 
(FP7) Science Advisory Board in Health, Brussels, Belgium
2006-2012:  Chair of the Scientific Advisory Board (SAB) of the Jenner 
institute, Oxford, UK
2008-2010:  Member of the Board of Trustees (BOT) of the international 
Vaccine institute (iVi), Seoul, republic of Korea
2006-2010:   Member of the Scientific Advisory Group (SAG) of the In-
ternational Vaccine institute (iVi), Seoul, republic of Korea
2005-2010:  Member of the Scientific Consultants Group (SCG) of the 
Malaria Vaccine Development Program of the U S  Agency 
37
for international Development (USAiD), Washington DC, 
USA
2003-2010:  Member of the Scientific Advisory Committee (SAC) of the 
european Vaccine initiative (eVi), Heidelberg, Germany 
– previously european Malaria Vaccine initiative (eMVi), 
Copenhagen, Denmark
2003-2010:  Member of the european Developing Country Clinical 
Trials Partnership (eDCTP) Partnership Board, The Hague, 
netherlands
2003-2010:  Member of the Scientific Advisory Committee, International 
AiDS Vaccine initiative (iAVi), new york, USA
2003-2008:  Member of the Board of Counsellors (BOC) of the Pediatric 
Dengue Vaccine initiative (PDVi) at iVi, Seoul, republic of 
Korea
2000-2002:  Member of the Project Management Subcommittee (Chair 
from 2003 to 2010), international AiDS Vaccine initiative 
(iAVi), new york, USA
1999-2002:  Advisor to the Director-General in the fields of Biotechnolo-
gy and innovation, inSerM, Paris, France
1997-2001:  Member of ArC (Association pour la recherche contre le 
Cancer) Virology/Immunology Scientific Committee, Paris, 
France
1998-2000:  Chair of WHO/TDr steering committee on Vaccine Disco-
very research (VDr), Geneva, Switzerland
1998-2000:  Member of AnrS (Agence nationale pour la recherche sur 
le SIDA) Virology Scientific Committee, Paris, France
1999:  Chair of the european Framework Program 5 (FP5), Quality 
of life external expert Monitoring panel, Brussels, Belgium
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1998:  Chair of the european FP4 Biomed external expert Monito-
ring panel, Brussels, Belgium
1994-1997:  Member of WHO/TDr steering committee on Malaria vac-
cines (iMMAl), Geneva, Switzerland
Prizes and distinctions:
2017: Prix international de l’inserm
2016:  Chevalier de la légion d’Honneur, au titre du Ministère des 
Affaires etrangères
2000:   Chevalier de l’Ordre national du Mérite, au titre du Minis-
tère de la recherche
1994: Prix Génération 2000-impact Médecin
1991: Prix de l’innovation rhône-Poulenc
Education:
2016:  executive High Performance Boards program of the inter-
national institute for Management Development (iMD) in 
lausanne (Switzerland)
2014:   Global Health Diplomacy, executive Course at the Graduate 
institute of international and Development Studies, Geneva 
(Switzerland)
1995:  Diplôme d’Habilitation à Diriger des recherches, Universi-
ty of Strasbourg (France)
1980: PhD-Thesis of the University of Montpellier (France)
1978: DeA of the University of Montpellier
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Languages: 
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ACORD 44/2018 en relació amb el punt 8 de l’ordre del dia de la sessió del 
Consell de Govern de data 3 de maig de 2018: Nomenaments de doctors 
honoris causa en commemoració del 50è aniversari de la UAB.
Vista la proposta de l’equip de Govern pel qual se sol·licita al Consell de Go-
vern, en commemoració del 50è aniversari de la UAB, el nomenament de la doc-
tora linda randall, del senyor Jaume Plensa Suñé, de la senyora Caddy Abduza, 
de la doctora Marie-Paule Kieny, i del senyor Joaquim Maria Puyal Ortiga, com 
a doctores i doctors honoris causa de la Universitat Autònoma de Barcelona 
Atès que tant del currículum de les candidates i dels candidats com de la docu-
mentació referent als seus mèrits i de les circumstàncies que concorren, queda 
acreditat que la seva activitat en el camp de la docència i de la recerca les i els 
fan mereixedors d’obtenir la distinció de doctor honoris causa de la Universitat 
Autònoma de Barcelona 
Atès que l’article 3 1 b la normativa que regula el procediment per a l’ator-
gament del títol de doctor Honoris Causa aprovada pel Consell de Govern 
en data 26 de maig de 2004 estableix que la iniciativa per a la proposta de 
nomenament de doctor honoris causa por partir, excepcionalment, del rector a 
proposta de l’equip de govern 
Ateses les circumstàncies excepcionals referents a la commemoració del 50è 
aniversari de la UAB, la rectora, a proposta de l’equip de Govern, presenta al 
Consell de Govern aquesta proposta de nomenaments com a doctores i doctors 
honoris causa de la UAB 
Vista la conformitat del Gabinet Jurídic 
Per tot això, a la vista de les consideracions anteriors, a proposta de la rectora, 
el Consell de Govern ha adoptat els següents
ACORDS
Primer - nomenar la doctora lisa randall, el senyor Jaume Plensa Suñé, la 
senyora Caddy Abduza, la doctora Marie-Paule Kieny, i el senyor Joaquim 
Maria Puyal Ortiga, doctores i doctors honoris causa de la UAB 
Segon - encarregar a la secretària general i al vicerector de relacions institu-
cionals i de Cultura l’execució i el seguiment d’aquest acord 
Bellaterra (Cerdanyola del Vallès), 3 de maig de 2018

